AbbVie lowered its full-year adjusted EPS guidance to $13.97 at the midpoint, a 1.5% decrease, even as second-quarter revenue rose 10.2% year-on-year to $16.99 billion, beating analyst estimates of $16.79 billion. Adjusted EPS of $3.65 also exceeded the $3.61 consensus. CEO Robert Michael highlighted over 20% growth in both the immunology and neuroscience portfolios, with SKYRIZI achieving market leadership in multiple countries. During the earnings call, analysts pressed management on SKYRIZI's subcutaneous induction timeline, competitive dynamics in psoriasis, and the Tevapadon launch in Parkinson's disease, while executives expressed confidence in pipeline progress and manufacturing readiness.
AbbVie IncAbbVie lowered full-year adjusted EPS guidance by 1.5% despite Q2 beat.
